Exelixis Interest Expense 2011-2025 | EXEL

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Exelixis

2025	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-133 K	93 K	-197 K	-184 K	-	-	-	8.68 M	33.1 M	48.7 M	48.6 M	45.3 M	27.1 M	16.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
48.7 M	-197 K	20.7 M

Quarterly Interest Expense Exelixis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-49 K	50 K	-245 K	-	-29 K	-287 K	-89 K	-	289 K	-5 K	-54 K	-	-69 K	45 K	164 K	-	-19 K	-11 K	-90 K	-	565 K	-	6 K	-	-140 K	803 K	25 K	-	1 K	-	-	-	-	4.26 M	4.42 M	-	7.83 M	10.5 M	10.3 M	-	40.7 M	12 M	12.4 M	-	12.3 M	12.1 M	11.8 M	-	11.4 M	11.2 M	11.1 M	-	7.68 M	4.09 M	4 M	-	4.14 M	4.16 M	3.94 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
40.7 M	-287 K	4.9 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	459 K	$ 4.85	2.87 %	$ 805 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.21	-1.23 %	$ 248 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Aptevo Therapeutics APVO	472 K	$ 1.06	-6.64 %	$ 293 K	USA
Ascendis Pharma A/S ASND	65.5 M	$ 215.41	-2.27 %	$ 5 B	Danmark
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.15	-3.85 %	$ 7.58 B	Australia
BioVie BIVI	4.3 M	$ 1.43	-1.39 %	$ 2.11 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.2	3.68 %	$ 1.27 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.27	-6.08 %	$ 588 M	Israel
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 13.48	-4.36 %	$ 887 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Axon Enterprise AXON	286 M	$ 549.1	-2.69 %	$ 41.6 B	USA
Aytu BioScience AYTU	-512 K	$ 2.4	4.34 %	$ 15.1 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.23	-2.69 %	$ 726 M	USA
Biogen BIIB	250 M	$ 174.94	0.48 %	$ 25.5 B	USA
Abeona Therapeutics ABEO	418 K	$ 5.07	-5.5 %	$ 108 M	USA
Celldex Therapeutics CLDX	927 K	$ 27.11	-1.47 %	$ 1.75 M	USA
ADiTx Therapeutics ADTX	5.84 K	$ 1.66	-25.84 %	$ 21.9 K	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA